PATENT CLAIM ANALYSIS

Application Number: 16042284
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-08
Patent Classification: ["530", "333000"]

Abstract:
The embodiments herein disclose a method for synthesizing antagonistic peptide VEGF and bFGF. The method comprises synthesizing the antagonistic peptide for VEGF and bFGF and analyzing the purity of peptides. The quality of antagonistic peptide for VEGF and bFGF is analyzed by HPLC chromatogram and Mass spectrometry analysis. The biochemical activity of the antagonistic peptide for VEGF and bFGF is analyzed by competitive binding assay, cell proliferation assay, Matrigel assay for anti-angiogenic activity analysis, histopathological staining and Western blot analysis. The competitive binding assay of antagonistic peptide for VEGF and bFGF illustrate that peptides binds with cell receptors at a concentration of 2000 ng/ml. The cell proliferation assay illustrates that cell growth is arrested when antagonistic peptide for VEGF and bFGF are at a concentration of 2000 ng/ml. The anti-angiogenic activity analysis illustrates that angiogenesis is arrested when the concentration of antagonistic peptide for VEGF and bFGF is 2000 ng/ml.

Claim (Index 7):
The method according to  claim 1 , wherein the Seq. ID No.5 peptide comprises amino acid residues derived from bFGF, and wherein Seq. ID No.5 comprises of amino acid residues 115-136 in bFGF, and wherein the Seq. ID No.5 comprises a biochemical structure represented by  2 HN-Leu 119 -Lys 120 -Arg 121 -Thr 122 -Gly 123 -Gln 124 -Tyr 125 -Lys 126 -Leu 127 -COOH, and wherein a plurality of cysteine residues are added optionally to the N-terminus and C-terminus of Seq.ID No.5 for chain cyclization, and wherein cysteine residues are added to the N-terminus and C-terminus of Seq.ID No.5 to obtain a biochemical structure represented by  2 HN-Cys-Leu-Lys-Arg-Thr-Gly-Gln-Tyr-Lys-Leu-Cys-COOH, and wherein the Seq. ID No.5 peptide bind and blocks a basic fibroblast growth fhctor-receptors I1 (bFGFR-1), and wherein the Seq. ID No.5 peptide binds and blocks vascular endothelial. growth factor receptor 1 (VEGFR-1) and/or vascular endothelial growth factor receptor2 (VEGFR-2) and basic fibroblast growth factor-receptor 1 (bFGFR-1) with a predetermined combination of Seq. ID No. 5 peptide and with at least one of Seq. ID No. 1 to Seq. ID No. 4.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 95.0
- Lexical Diversity: 2.75862
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15222237', '10263162', '10046922', '13713594', '13662024']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6444200669731983
- 35 USC 102 Novelty (BERT): 0.5455074867612297
- Combined Prediction Score: 0.6345288089520015
- Mean Citation Score: 381.339348
- Max Citation Score: 398.11826
- Similarity Product: 236.74181838675145

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test